Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act or the SCREENS for Cancer Act of 2022 This bill reauthorizes through FY2027 and makes changes to the National Breast and Cervical Cancer Early Detection Program. This program provides funding to states for breast and cervical cancer screening, diagnostic, and treatment services for individuals who have low incomes, are uninsured, or otherwise lack access to such services.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2023 · fourth_quarter · Health Issues
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
MetastaticBreastCancerAccess to Care Act; HR 8185 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; H.R. 235 - Triple-Negative Breast Cancer Research and Education Act of 2023; H.R. 9565 - Comprehensive Cancer Survivorship Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
MetastaticBreastCancerAccess to Care Act; HR 8185 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; H.R. 235 - Triple-Negative Breast Cancer Research and Education Act of 2023; H.R. 9565 - Comprehensive Cancer Survivorship Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
MetastaticBreastCancerAccess to Care Act; HR 8185 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; H.R. 235 - Triple-Negative Breast Cancer Research and Education Act of 2023; H.R. 9565 - Comprehensive Cancer Survivorship Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
MetastaticBreastCancerAccess to Care Act; HR 8185 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; H.R. 235 - Triple-Negative Breast Cancer Research and Education Act of 2023; H.R. 9565 - Comprehensive Cancer Survivorship Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 379/S. 104 - Improving Social Determinants of Health Act; bill to require the Centers for Disease Control and Prevention (CDC) to establish a program to improve health outcomes and reduce health inequities by, for example, coordinating activities across the CDC. As part of the program, the CDC must award grants to eligible organizations to build capacity to address social determinants of health. H.R. 469 - Comprehensive Breast Reconstruction Act of 2021; bill provides for Medicare, Medicaid, and private health insurance coverage of certain tattooing services in connection with post-mastectomy breast reconstruction, and aligns the scope of Medicare and Medicaid coverage of such breast reconstruction with that of private health insurance. H.R. 5030/S.2706 - DIVERSE Trials Act; A bill to require FDA to issue guidance on decentralized clinical trials to promote meaningful demographic/geographic diversity in patient engagement, expand reporting by laboratories that test for and diagnose COVID-19, and require a study on data collection and data sharing during public health emergencies H.R. 6000 - Cures 2.0 Act; a comprehensive healthcare and biomedical research bill H.R. 4794/S. 2533 - Making Advances in Mammography and Medical Options for Veterans Act; a bill to improve mammography services furnished by the Department of Veterans Affairs H.R. 4571/S. 2102 - Supporting Expanded Review for Veterans in Combat Environments (SERVICE) Act of 2021; a bill to expand eligibility for Veterans Health Administration mammography screenings to veterans who served in certain locations during specified periods, including those who were exposed to toxic substances at such locations H.R. 6584 - Diverse and Equitable Participation in Clinical Trials (DEPICT) Act; a bill to direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes. S. 3799 - Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; a bill to prepare for, and respond to, existing viruses, emerging new threats, and pandemics. H.R. 7845 NIH Clinical Trial Diversity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 8185/S. 4440 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2023 through 2027 S. 4260 - Palliative Care and Hospice Education and Training Act; a bill to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools, social work schools, and other programs, including physician assistant education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative medicine. H.R. 7667/S. 4348 - Food and Drug Amendments of 2022; a bill to reauthorize Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices. H.R. 9565/S. 5295- Comprehensive Cancer Survivorship Act; a bill to address the health of cancer survivors and unmet needs that survivors face through the entire continuum of care from diagnosis through active treatment and posttreatment, in order to improve survivorship, treatment, transition to recovery and beyond, quality of life and palliative care, and long-term health outcomes, including by developing a minimum standard of care for cancer survivorship, irrespective of the type of cancer, a survivors background, or forthcoming survivorship needs, and for other purposes. Policies related to telehealth Policies to increase clinical trial diversity and access for underrepresented populations Policies related to genetic counseling and testing Policies related to cancer survivorship Policies related to PBM and drug cost transparency Policies related to the reauthorization of FDA User Fee Agreements Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 Policies related to the implementation of the Mammography Quality Standards Act Policies related to administration actions necessary in breast imaging and breast cancer diagnosis Comments regarding a request for information on establishing a National Directory of Healthcare Providers and Services
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2022 · fourth_quarter · Health Issues
Health disparities Access to clinical trials for underrepresented populations Improving Social Determinants of Health Act (S.104/H.R.379) Comprehensive Breast Reconstruction Act of 2021 (H.R. 469) DIVERSE Trials Act (H.R. 5030/S. 2706) Diverse and Equitable Participation in Clinical Trials (DEPICT) Act (H.R.6584); a bill to direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes CURES 2.0 Act (H.R. 6000) Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to COVID-19 vaccination distribution Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Policies related to genetic counseling and screening Policies related to reauthorization of user fees at the Food and Drug Administration (H.R. 7667/ S. 4348) H.R. 7845 NIH Clinical Trial Diversity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 8185/S. 4440 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2023 through 2027 Advanced Research Project Agency-Health Act (H.R.5585) Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT) Pandemics Act (S.3799) Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 H.R. 9565/S. 5295- Comprehensive Cancer Survivorship Act Policies related to the reauthorization of FDA User Fee Agreements Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 Policies related to the implementation of the Mammography Quality Standards Act Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis Policies related to the regulation of diagnostic devices Section 1557, Nondiscrimination in Health Programs and Activities (RIN Number 0945-AA17) Request for Information on establishing a National Directory of Healthcare Providers and Services
2022 · fourth_quarter · Health Issues
Issues related to drug pricing Issues related to triple negative breast cancer HR 8185 - SCREENS for Cancer Act Issues related to TRIPS waiver Issues related to TNBC & CAR T Therapy/Cancer Moonshot
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Health Issues
H.R. 379/S. 104 - Improving Social Determinants of Health Act; bill to require the Centers for Disease Control and Prevention (CDC) to establish a program to improve health outcomes and reduce health inequities by, for example, coordinating activities across the CDC. As part of the program, the CDC must award grants to eligible organizations to build capacity to address social determinants of health. H.R. 469 - Comprehensive Breast Reconstruction Act of 2021; bill provides for Medicare, Medicaid, and private health insurance coverage of certain tattooing services in connection with post-mastectomy breast reconstruction, and aligns the scope of Medicare and Medicaid coverage of such breast reconstruction with that of private health insurance. H.R. 5030/S.2706 - DIVERSE Trials Act; A bill to require FDA to issue guidance on decentralized clinical trials to promote meaningful demographic/geographic diversity in patient engagment, expand reporting by laboratories that test for and diagnose COVID-19, and require a study on data collection and data sharing during public health emergencies H.R. 6000 - Cures 2.0 Act; a comprehensive healthcare and biomedical research bill H.R. 4794/S. 2533 - Making Advances in Mammography and Medical Options for Veterans Act; a bill to improve mammography services furnished by the Department of Veterans Affairs H.R. 4571/S. 2102 - Supporting Expanded Review for Veterans in Combat Environments (SERVICE) Act of 2021; a bill to expand eligibility for Veterans Health Administration mammography screenings to veterans who served in certain locations during specified periods, including those who were exposed to toxic substances at such locations H.R. 6584 - Diverse and Equitable Participation in Clinical Trials (DEPICT) Act; a bill to direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes. S. 3799 - Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; a bill to prepare for, and respond to, existing viruses, emerging new threats, and pandemics. Efforts to introduce a bill regarding clinical trial diversity nicknamed the The Clinical Trial Diversity Act H.R. 7845 NIH Clinical Trial Diversity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 8185/S. 4440 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2023 through 2027 S. 4260 - Palliative Care and Hospice Education and Training Act; a bill to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools, social work schools, and other programs, including physician assistant education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative medicine. H.R. 7667/S. 4348 - Food and Drug Amendments of 2022; a bill to reauthorize Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices. Policies related to telehealth Policies related to COVID-19 vaccination and monoclonal antibody distribution Policies to increase clinical trial diversity and access for underrepresented populations Policies related to genetic counseling and testing Policies related to cancer survivorship Policies related to PBM and drug cost transparency Policies related to the reauthorization of FDA User Fee Agreements Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017
2022 · third_quarter · Health Issues
Health disparities Access to clinical trials for underrepresented populations Improving Social Determinants of Health Act (S.104/H.R.379) Comprehensive Breast Reconstruction Act of 2021 (H.R. 469) DIVERSE Trials Act (H.R. 5030/S. 2706) Diverse and Equitable Participation in Clinical Trials (DEPICT) Act (H.R.6584); a bill to direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes CURES 2.0 Act (H.R. 6000) Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to COVID-19 vaccination distribution Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Policies related to genetic counseling and screening Policies related to reauthorization of user fees at the Food and Drug Administration (H.R. 7667/ S. 4348) H.R. 7845 NIH Clinical Trial Diversity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 8185/S. 4440 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2023 through 2027 Advanced Research Project Agency-Health Act (H.R.5585) Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT) Pandemics Act (S.3799) Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017
2022 · third_quarter · Health Issues
Issues related to drug pricing and manufacturing Issues related to triple negative breast cancer HR 8185 - SCREENS for Cancer Act
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Health Insurance Coverage (general); Health Equity (general); Breastfeeding (general); Assisted Reproductive Technology (general); Substance Use Disorder (general); Gynecologic Cancer (general); Reproductive Health (general); Intimate Partner Violence (general); Gun Violence (general); Immunization (general); Breast Cancer (general); Medical Liability Reform (general); Health IT (general); Patient-Physician Relationship (general); Child Welfare (general); Maternal Mortality and Morbidity (general); Graduate Medical Education (general); Contraception (general); Abortion (general); Indian Health (general); Teaching Health Centers Graduate Medical Education (general); Community Health Centers (general); National Health Service Corps (general); Health care workforce (general); Title VII Health Workforce Programs (general); Title VIII Health Workforce Programs (general); Sexuality Education (general); Sexually Transmitted Infections (general); Access and Provision of Medication-based Opioid Use Disorder Treatment (HHS); Research in Pregnant and Breastfeeding Women (general); Health Care Reform (general); Title X Family Planning Program (general); Womens Preventive Services (general); Administrative Burden (general); COVID-19 Response (general); COVID-19 Vaccines (general); Pandemic Preparedness (general); Risk Evaluation and Mitigation Strategies (general); Data Collection (general); Social Determinants of Health (General); Maternal Mental Health (general); Online misinformation (general); EMTALA (general); H.R. 3755/S. 1975, Womens Health Protection Act; implementation of P.L. 115-320, Improving Access to Maternity Care Act; implementation of Maternal Health Quality Improvement Act contained in P.L. 117-103; H.R. 959/ S. 346, Black Maternal Health Momnibus Act; implementation of P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; implementation of P.L. 116-127, the Families First Coronavirus Response Act; implementation of P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act; implementation of P.L. 116-139, Paycheck Protection Program and Health Care Enhancement Act; H.R. 1065/S. 1486, Pregnant Workers Fairness Act; implementation of P.L. 117-105, Lorna Breen Health Care Provider Protection Act H.R. 1350/ S.408, Supporting Best Practices for Healthy Moms Act; H.R. 3407/S. 411, MOMMAs Act; implementation of P.L. 117-2, the American Rescue Plan Act of 2021; H.R. 2007/S. 2444, Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021; H.R. 3110/S. 1658, PUMP for Nursing Mothers Act; H.R. 2903/S.1515, CONNECT for Health Act; H.R. 3671/S.1958, Doctors of Community (DOC) Act; Implementation of P.L. 114-255, the 21st Century Cures Act; Implementation of the No Surprises Act contained in P.L. 116-260H.R. 482/S. 350, Newborn Screening Saves Lives Reauthorization Act; H.R. 804/S. 248, FAMILY Act; H.R. 5/S. 393, Equality Act; H.R. 4151/S. 2238, FASD Respect Act; Advanced Research Projects Agency for Health (ARPA-H); H.R. 5376, Build Back Better Act, H.R. 5376, Inflation Reduction Act of 2022; H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act; H.R. 5239/ S. 2941, Good Samaritan Health Professionals Act of 2021; H.R. 7073/S.3824, Into the Light for MMH and SUD Act of 2022; H.R.5487/S.3972, SHINE for Autumn Act of 2021; Maternal, Infant, and Early Childhood Home Visiting Program (MIECHV) (general); Disclosure of Ingredients in Menstrual Products (general); H.R.7011/S.3797, Maternal and Child Health Stillbirth Prevention Act of 2022; H.R. 2234/S. 1021, Equal Access to Abortion Coverage (EACH) Act; S. 4467, Protecting Access to Medication Abortion Act; S.Res.664, A resolution expressing opposition to the criminalization of essential healthcare, including the full range of sexual and reproductive healthcare such as abortion, gender-affirming care, and contraceptive care, and disapproving of the criminalization of pregnancy outcomes; H.Res.589, Expressing the sense of the House of Representatives that policies governing access to medication abortion care in the United States should be equitable and based on science; H.R. 7894/S. 4347, Affordability is Access Act (AAA); H.R. 6005/S. 3223, Access to Birth Control Act; H.R. 7845, NIH Clinical Trial Diversity Act of 2022; H.R. 4217/S. 2779, TRIUMPH for New Moms Act of 2021; H.R. 7974, Endometriosis CARE Act of 2022; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022; H.R. 8185/S. 4440 Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; H.R. 7617/S. 309, Preventive Care Awareness Act of 2022; Safety and efficacy of noninvasive prenatal screening tests (FDA/CMS); COVID-19 public health emergency unwinding (general); ; Implementation of the Maternal Health Quality Improvement Act and Rural MOMS Act included in P.L. 117-103; Implementation of P.L. 117-103, Consolidated Appropriations Act, 2022;; health care provider conscience protections (general); Access to prenatal telehealth services (general) ; H.R. ____, Abortion Care Awareness Act; Consent for use of human reproductive material in assisted reproductive technology or intrauterine insemination (general); H.R. ____, Informing New Factors and Options for Reproductive Care Act; H.R. 8834, EQUIP Act; S. 4688, Reproductive Freedom for All Act; S. 4748, Protecting National Access to Reproductive Care Act; H.R. 4040, Advancing Telehealth Beyond COVID-19 Act of 2021; Reproductive health care workforce (general); S.4467, Protecting Access to Medication Abortion Act; S.4723, Let Doctors Provide Reproductive Health Care Act; H.R. 8373, Right to Contraception Act; S.4764, Reproductive Health Care Accessibility Act
2022 · second_quarter · Health Issues
H.R. 379/S. 104 - Improving Social Determinants of Health Act; bill to require the Centers for Disease Control and Prevention (CDC) to establish a program to improve health outcomes and reduce health inequities by, for example, coordinating activities across the CDC. As part of the program, the CDC must award grants to eligible organizations to build capacity to address social determinants of health. H.R. 469 - Comprehensive Breast Reconstruction Act of 2021; bill provides for Medicare, Medicaid, and private health insurance coverage of certain tattooing services in connection with post-mastectomy breast reconstruction, and aligns the scope of Medicare and Medicaid coverage of such breast reconstruction with that of private health insurance. H.R. 5030/S.2706 - DIVERSE Trials Act; A bill to require FDA to issue guidance on decentralized clinical trials to promote meaningful demographic/geographic diversity in patient engagment, expand reporting by laboratories that test for and diagnose COVID-19, and require a study on data collection and data sharing during public health emergencies H.R. 6000 - Cures 2.0 Act; a comprehensive healthcare and biomedical research bill H.R. 4794/S. 2533 - Making Advances in Mammography and Medical Options for Veterans Act; a bill to improve mammography services furnished by the Department of Veterans Affairs H.R. 4571/S. 2102 - Supporting Expanded Review for Veterans in Combat Environments (SERVICE) Act of 2021; a bill to expand eligibility for Veterans Health Administration mammography screenings to veterans who served in certain locations during specified periods, including those who were exposed to toxic substances at such locations H.R. 6584 - Diverse and Equitable Participation in Clinical Trials (DEPICT) Act; a bill to direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes. S. 3799 - Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; a bill to prepare for, and respond to, existing viruses, emerging new threats, and pandemics. Efforts to introduce a bill regarding clinical trial diversity nicknamed the The Clinical Trial Diversity Act H.R. 7845 NIH Clinical Trial Diversity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 8185/S. 4440 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2023 through 2027 S. 4260 - Palliative Care and Hospice Education and Training Act; a bill to increase the number of permanent faculty in palliative care at accredited allopathic and osteopathic medical schools, nursing schools, social work schools, and other programs, including physician assistant education programs, to promote education and research in palliative care and hospice, and to support the development of faculty careers in academic palliative medicine. H.R. 7667/S. 4348 - Food and Drug Amendments of 2022; a bill to reauthorize Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices. Policies related to telehealth Policies related to COVID-19 vaccination and monoclonal antibody distribution Policies to increase clinical trial diversity and access for underrepresented populations Policies related to genetic counseling and testing Policies related to cancer survivorship Policies related to PBM and drug cost transparency Comments to FTC regarding a Request for Information on Pharmacy Benefit Managers practices (FTC-2022-0015) Comments to FDA on the Draft Guidance For Industry: Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials (FDA-2021-D0789)
2022 · second_quarter · Health Issues
Health disparities Access to clinical trials for underrepresented populations Improving Social Determinants of Health Act (S.104/H.R.379) Comprehensive Breast Reconstruction Act of 2021 (H.R. 469) DIVERSE Trials Act (H.R. 5030/S. 2706) Diverse and Equitable Participation in Clinical Trials (DEPICT) Act (H.R.6584); a bill to direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes CURES 2.0 Act (H.R. 6000) Policies related to cancer survivorship Policies related to medications access in during emergencies Polices related to PBM and drug cost transparency Policies related to COVID-19 vaccination distribution Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution Policies related to reducing the cost of cancer treatment for patients Policies related to decline in breast cancer screenings during the COVID-19 pandemic Policies related to genetic counseling and screening Policies related to reauthorization of user fees at the Food and Drug Administration (H.R. 7667/ S. 4348)H.R. 7845 NIH Clinical Trial Diversity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes. H.R. 8185/S. 4440 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2023 through 2027 Advanced Research Project Agency-Health Act (H.R.5585) Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT) Pandemics Act (S.3799) Comments to the FDA on Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry (FDA-2021-D0789) Comments to the FTC on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers (FTC-2022-0015)
2022 · second_quarter · Health Issues
Health Insurance Coverage (general); Health Disparities (general); Breastfeeding (general); Assisted Reproductive Technology (general); Smoking Cessation (general); Substance Use Disorder (general); Gynecologic Cancer (general); Gynecologic Devices (general); Reproductive Health (general); Intimate Partner Violence (general); Gun Violence (general); Immunization (general); Breast Cancer (general); Medical Liability Reform (general); Health IT (general); Patient-Physician Relationship (general); Child Welfare (general); Prematurity (general); Maternal Mortality and Morbidity (general); Graduate Medical Education (general); Contraception (general); Abortion (general); Mifepristone (general); Indian Health (general); Teaching Health Centers Graduate Medical Education (general); Community Health Centers (general); National Health Service Corps (general); Health care workforce (general); Title VII Health Workforce Programs (general); Title VIII Health Workforce Programs (general); Special Diabetes Program (general); Special Diabetes Program for Indians (general); Sexuality Education (general); Teen Pregnancy Prevention Program (general); Personal Responsibility Education Program (general); Sexually Transmitted Infections (general); Access and Provision of Medication-based Opioid Use Disorder Treatment (HHS); Research in Pregnant and Breastfeeding Women (general); Health Care Reform (general); Title X Family Planning Program (general); Womens Preventive Services (general); Administrative Burden (general); COVID-19 Response (general); Risk Evaluation and Mitigation Strategies (general); Data Collection (general); Health Equity (general); Social Determinants of Health (General) Pregnancy Risk Assessment Monitoring System (CDC); Provider Relief Fund (general); Maternal Mental Health (general); Violence Against Women Act (general); COVID-19 Vaccine (general); H.R. 3755/S. 1975, Womens Health Protection Act; implementation of P.L. 115-344, Preventing Maternal Deaths Act; implementation of P.L. 115-320, Improving Access to Maternity Care Act; H.R. 4387/S.1675, Maternal Health Quality Improvement Act; H.R. 959/ S. 346, the Black Maternal Health Momnibus Act of 2021; implementation of P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020; implementation of P.L. 116-127, the Families First Coronavirus Response Act; implementation of P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act; implementation of P.L. 116-139, Paycheck Protection Program and Health Care Enhancement Act; H.R. 3021 the Coronavirus Provider Protection Act; H.R. 1065/S. 1486, the Pregnant Workers Fairness Act; implementation of P.L. 117-105, Lorna Breen Health Care Provider Protection Act; S. 176, Ensuring Understanding of COVID-19 to Protect Public Health Act; H.R. 736/S. 167, Community Immunity During COVID-19 Act; H.R. 1350/ S.408, Supporting Best Practices for Healthy Moms Act; H.R. 3407/S. 411, MOMMAs Act; H.R. 769/S.1491, Rural MOMS Act; implementation of P.L. 117-2, the American Rescue Plan Act of 2021; H.R. 2216 /S.1063, the Jeanette Acosta Invest in Womens Health Act; H.R. 2007/S. 2444, Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021; H.R. 3110/S. 1658, PUMP for Nursing Mothers Act; H.R. 2903/S.1515, CONNECT for Health Act; H.R. 3671/S.1958, Doctors of Community (DOC) Act; Implementation of P.L. 114-255, the 21st Century Cures Act; Implementation of the No Surprises Act contained in P.L. 116-260, Consolidated Appropriations Act, 2021; S. 1234/H.R. 2556, the Maternal CARE Act; S. 1333, the MOMS Act; S. 198/H.R. 1218, the Data Mapping to Save Moms Lives Act; H.R. 1439, Expanded Genetic Screening Act of 2021; S. 1622, the HEALTH for MOM Act of 2021; H.R. 482/S. 350, Newborn Screening Saves Lives Reauthorization Act; H.R. 804/S. 248, FAMILY Act; H.R. 5/S. 393, Equality Act; H.R. 4151/S. 2238, FASD Respect Act; H.R. 6000, Cures 2.0 Act; Advanced Research Projects Agency for Health (ARPA-H); H.R. 5376/S.___, Build Back Better Act; H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act; H.R. 5239/ S. 2941, Good Samaritan Health Professionals Act of 2021; H.R. 4576/S. 2390, Support Through Loss Act; H.R 6143, Supporting Health Care Providers During the COVID-19 Pandemic Act; H.R. 7073/S.3824, Into the Light for MMH and SUD Act of 2022; H.R.5487/S.3972, SHINE for Autumn Act of 2021; Maternal, Infant, and Early Childhood Home Visiting Program (MIECHV) (general); H.R.4128/ S.2209, VALID Act of 2021; Pandemic Preparedness (general); S.3799, PREVENT Pandemics Act; S.Res.560, A resolution recognizing the significance of endometriosis as an unmet chronic disease for women and designating March 2022 as "Endometriosis Awareness Month"; Disclosure of Ingredients in Menstrual Products (general); H.R.7011/S.3797, Maternal and Child Health Stillbirth Prevention Act of 2022; Healthy Start Program (HRSA); Tobacco Product Standard for Characterizing Flavors in Cigars (OMB); Tobacco Product Standard for Menthol in Cigars (OMB); H.R. 2234/S. 1021, Equal Access to Abortion Coverage (EACH) Act; S. 4467, Protecting Access to Medication Abortion Act; S.Res.664, A resolution expressing opposition to the criminalization of essential healthcare, including the full range of sexual and reproductive healthcare such as abortion, gender-affirming care, and contraceptive care, and disapproving of the criminalization of pregnancy outcomes; H.Res.589, Expressing the sense of the House of Representatives that policies governing access to medication abortion care in the United States should be equitable and based on science; H.R. 7894/S. 4347, Affordability is Access Act (AAA); H.R. 6005/S. 3223, Access to Birth Control Act; H.R. 7845, NIH Clinical Trial Diversity Act of 2022; H.R. 4217, TRIUMPH for New Moms Act of 2021; H.R.7974 - Endometriosis CARE Act of 2022; H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022; H.R. 8185/S. 4440 Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; H.R. 7617/S. 309, Preventive Care Awareness Act of 2022; H.Res.1072/S.Res.602, Expressing support for the designation of April 30, 2022, as "National Adult Hepatitis B Vaccination Awareness Day"; Safety and efficacy of noninvasive prenatal screening tests (FDA/CMS); COVID-19 public health emergency unwinding (general); ; Implementation of the Maternal Health Quality Improvement Act and Rural MOMS Act included in P.L. 117-103H.R.2471, Consolidated Appropriations Act, 2022; fertility fraud and assisted reproductive technology (general); health care provider conscience protections (general).
| Republican |
| NE |
| Gwen Moore | Democratic | WI |
| James P. McGovern | Democratic | MA |
| Madeleine Dean | Democratic | PA |
| Maria Elvira Salazar | Republican | FL |
| Mike Bost | Republican | IL |
| Nanette Diaz Barragán | Democratic | CA |
| Tom Cole | Republican | OK |
Client expense: Not reported · Firm income: $40,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Client expense: Not reported · Firm income: $42,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Client expense: $110,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Client expense: Not reported · Firm income: $42,000
Government targets: Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Client expense: $110,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office